Yuhan is taking a "select and focus" R&D approach in line with rapidly changing global new drug trends. As part of this strategy, it is focusing on cancer, metabolic disease/obesity and immunology.
This year, it aims to pursue “more aggressive and bolder” internalization of innovative technologies to diversify R&D capabilities and establish a virtuous R&D cycle for future growth.
The company it making thorough preparations to launch Leclaza as a global innovative drug and focusing investment in strategic projects to speed up the launch of subsequent new drugs. It is aiming to expand pipeline assets at each development stage.

Toward The Global Big Pharma League: Yuhan’s Ambitions After Leclaza

Looking To Transcend Korean Pharma's Limits